Clinicopathological correlates of pyramidal signs in multiple system atrophy

Chi-Ying R. Lin¹, Anisha Viswanathan²,³, Tiffany X. Chen²,³,⁴, Hiroshi Mitsumoto²,⁵, Jean P. Vonsattel⁶, Phyllis L. Faust⁶ & Sheng-Han Kuo²,³

¹Department of Neurology, Parkinson’s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas, USA
²Department of Neurology, Columbia University Irving Medical Center and the New York Presbyterian Hospital, New York, New York, USA
³Initiative for Columbia Ataxia and Tremor, Columbia University Irving Medical Center, New York, New York, USA
⁴Department of Biomedical Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, Maryland, USA
⁵Eleanor and Lou Gehrig ALS Center, Columbia University Irving Medical Center, New York, New York, USA
⁶Department of Pathology and Cell Biology, Columbia University Irving Medical Center and the New York Presbyterian Hospital, New York, New York, USA

Correspondence
Chi-Ying R. Lin, Department of Neurology, Baylor College of Medicine, Houston, TX, USA. Tel: 713-798-2273; Fax: 713-798-7434; E-mail: chi-ying.lin@bcm.edu

Funding Information
Dr. Kuo has received funding from the National Institutes of Health: NINDS #R01 NS104423 (principal investigator), NINDS #R01 NS114871 (principal investigator), Brain Research Foundation, National Ataxia Foundation, Parkinson’s Foundation, and International Essential Tremor Foundation. Dr. Faust has received funding from the National Institutes of Health: NINDS #R01 NS088257 (principal investigator).

Received: 17 December 2021; Revised: 23 April 2022; Accepted: 26 April 2022

Abstract

Objective: Pyramidal signs are common but often under-recognized in multiple system atrophy (MSA). The clinicopathological correlates of pyramidal signs in MSA are not well characterized. The present study aims to understand the role of pyramidal signs in MSA. Methods: We examined 40 autopsy-confirmed MSA cases in New York Brain Bank. The pyramidal signs were quantified by an established rating scale, summarized as the pyramidal score. We assessed whether pyramidal scores are associated with autonomic, parkinsonism, and cerebellar features and survival. We also examined whether the density of glial cytoplasmic inclusions (GCIs) in the motor cortex and its underlying white matter is associated with the pyramidal score. Results: MSA parkinsonian type cases have higher pyramidal scores compared to cerebellar type cases (p = 0.017). MSA cases with high pyramidal scores are more likely to have laryngeal stridor (OR = 4.89, p = 0.022), but less likely to have orthostatic hypotension (OR = 0.11, p = 0.006) and erectile dysfunction (OR = 0.05, p = 0.018). MSA cases with high pyramidal scores do not differ from those with low pyramidal scores in terms of bowel dysfunction, dry eyes and mouth, and survival. Finally, MSA cases with more GCIs in the motor cortex have higher pyramidal scores compared to those with few GCIs (p = 0.017). Interpretation: Pyramidal signs in MSA are associated with the parkinsonian subtype, laryngeal stridor, and certain autonomic dysfunction.

Introduction

Multiple system atrophy (MSA) is an adult-onset, sporadic, and relentlessly progressive neurodegenerative disease.¹,² The neuropathological hallmark for MSA is the glial cytoplasmic inclusion (GCI), reflecting alpha-synuclein deposition in glial cells in the nigrostriatal or/and olivo-ponto-cerebellar systems,³ leading to parkinsonism (MSA-P), and cerebellar ataxia (MSA-C) subtypes. MSA-P may have a faster disease progression than MSA-C,⁴ indicating that the predominant symptoms of MSA may have prognostic value. Another core feature for MSA is autonomic dysfunction, which occurs early and persists throughout the disease course.³

In addition to the above-mentioned three domains of MSA (parkinsonian, cerebellar, and autonomic), the fourth domain of neurological symptoms in the originally described MSA is in the pyramidal system, manifesting as pyramidal signs, such as hyperreflexia, extensor plantar responses, and spasticity.²,⁵–⁸ These pyramidal signs can provide important diagnostic clues for MSA in both parkinsonian and cerebellar subtypes.²,⁹–¹² Pyramidal
signs are due to damage in the pyramidal system from the motor cortex to corticospinal tract. These clinical observations can also be reflected in structural imaging studies, demonstrating pyramidal system degeneration in MSA.9 Neuropathological examination in the MSA motor cortex demonstrates astrocytosis, loss of Betz cells, and GCIs, along with reduced number of myelinated fibers in the spinal cord,11 which all supports the pyramidal involvement. In summary, these data support that this fourth domain of MSA may be part of the core clinical and pathological features.

Despite clear involvement of the pyramidal system in MSA, there is no study, to our knowledge, that investigates associations between pyramidal signs and other clinical landmarks in MSA. Additionally, there have been no studies evaluating pathologic correlates of clinical pyramidal signs in MSA. To address these knowledge gaps, we thus studied the associations between the pyramidal signs with other clinical features and pathological alterations in autopsy-confirmed MSA cases.

**Methods**

We studied autopsy-confirmed MSA cases from the New York Brain Bank at Columbia University.13 The study was approved by Columbia University Institutional Review Boards and the informed consents for brain donations were obtained for all cases. The presence of GCIs was confirmed by the standard alpha-synuclein immunohistochemistry staining (clone KM51, Novocasta Antibodies) and clear documentation by neuropathologists at Columbia University.13 Up until January 2021, the New York Brain Bank contains 40 MSA cases, and all of the cases were followed up in our Center for Parkinson’s disease and Other Movement Disorders Clinic during life. We conducted a retrospective review for all these 40 MSAs and recorded their clinical features in detail,7 including the pre-mortem diagnoses, dysautonomia (i.e., autonomic failure or dysfunction as defined by the MSA diagnostic consensus7), rapid eye movement behavior disorder (RBD, i.e., sleep behaviors such as arm thrashing, leg kicking, or falling out of bed in the context of dream enactment scenes; based on self-report or via sleep studies), stridor (i.e., based on physician’s questioning and/or patient’s self-report, described as a high-pitched, harsh, or strained breathing sound during inspiration especially during sleep or wakefulness14), dysarthria (i.e., change of the speech articulation clarity), and dysphagia (i.e., reported symptoms indicative of swallowing difficulty, such as “food stuck in the throat”), and the presence of dry eyes (i.e., patient’s self-report of dry-eye-related description, including but not limited to “a feeling of dryness, lack of saliva, burning of mouth”).15

**Assessment of pyramidal signs**

To quantitatively measure the severity of pyramidal signs, we used a published scale (i.e., pyramidal scores) developed for amyotrophic lateral sclerosis (ALS).16 In clinical practice, it could be difficult to assess whether the increased muscle tone is fully attributed to pyramidal involvement, especially for MSA-P cases who have rigidity. Thus, to avoid overestimating the assessment, we modified the scale by excluding the “muscle tone” domain. The details of this scale are listed in Table S1. We quantified deep tendon reflexes for each extremity and also counted the total numbers of Babinski signs, Trometer signs, brisk facial, and jaw jerks and forced yawn signs. The highest possible score is 20; we then divided the sum of the scores in each case by 20 to calculate the percentage as the “pyramidal score.”16 Each case is categorized into high pyramidal scores (P1: score ≥ 50) or low pyramidal scores (P1: score < 50). We compared the severity of pyramidal signs between MSA-P and MSA-C, as well as probable MSA and possible MSA, diagnosed during life.

**Neuropathologic investigation**

To determine the association between pyramidal scores and the density of GCIs, we developed a semi-quantitative scale for GCI density in the motor cortex as well as the white matter underlying the motor cortex (Brodman area 4 and 6): GCI score 0 = none, 1 = scantly/rare, 2 = scattered, and 3 = widespread (Fig. 1). We divided MSA cases into those with a higher GCI density (GCIH: GCI score ≥ 2) and those with low GCI density (GCIL: GCI score < 2). Considering that MSA has pathological involvement in the olivo-ponto-cerebellar systems, we also examined the presence of GCIs in the pontine base, inferior olivary nucleus, and cerebellar dentate as well as its adjacent white matter. The severity of the neuronal loss of motor cortex (0 = normal, 1 = relatively spared though not normal/mild loss, 2 = moderate loss, and 3 = marked/severe loss) and the neuronal cytoplasmic inclusion density of inferior olivary nucleus were also rated (0 = none, 1 = scantly/rare, 2 = scattered, and 3 = widespread). In addition, we studied the co-existent Alzheimer-type pathology using Braak and Braak Alzheimer’s Disease (AD) staging for neurofibrillary tangles17 and The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) staging18—a
National Institute of Aging-Reagan category (low, intermediate, and high probability of AD) was then assigned. We also studied the Lewy body disease pathology using Braak Lewy body staging. The pathological quantification was first performed by two neuropathologists when the brain was examined at the New York Brain Bank, and underwent a secondary inspection by experienced neuropathologists (P.L.F. and J.P.V.) before determining the final grading.

**Statistical analysis**

We investigated if PH and PL cases are more likely to have different subtypes of MSA (MSA-P vs. MSA-C) using chi-squared test. We also examined whether pyramidal scores differ between MSA-P and MSA-C using independent two-sample t-test. We conducted multivariable linear regression models to determine if the pyramidal scores are associated with survival, defined by the length of time from the time of diagnosis to the end of life, taking into account age, sex (male = 0, female = 1), and MSA types (MSA-C = 0, MSA-P = 1). We conducted logistic regression to examine whether the pyramidal scores are associated with other clinical features in MSA (PH = 0, PL = 1). We determined whether cases with higher GCI density (GCIH: GCI score ≥ 2) in the motor cortex and adjacent white matter as well as the olivo-ponto-cerebellar system have higher pyramidal scores compared to cases with low GCIs (GCI: GCI score < 2) using a chi-squared test. We also studied if the GCIs density in the motor cortex are different between MSA-P and MSA-C cases using independent two-sample t-test.

### Results

#### Demographics

In 40 autopsy-confirmed MSA cases, the average age of symptoms onset was 60.8 ± 7.7 years, and the age of death was 68.4 ± 7.2 years, with disease duration of 7.9 ± 2.7 years. There were 15 (35%) men and 25 (65%) women. The average pyramidal scores were 50.9 ± 16.7. In this cohort, the number of individuals with MSA-P (n = 27, 67.5%) was approximately twice of that of individuals with MSA-C (n = 13, 32.5%). Interestingly, the pyramidal scores were higher in MSA-P cases when compared to MSA-C cases (60.0 ± 7.5 vs. 41.9 ± 17.9, p = 0.017) (Table 1), indicating that MSA-P cases have more pyramidal signs, when compared to MSA-C cases. Consistently, hyperreflexia and Babinski sign were also more frequently seen in MSA-P cases (hyperreflexia: MSA-P 44% vs. MSA-C 15%; Babinski sign: MSA-P 48% vs. MSA-C 23%; Table S2). We found that the severity of pyramidal signs did not significantly differ between the

|               | MSA-P(n = 13) | MSA-C(n = 27) | p-value |
|---------------|---------------|---------------|---------|
| Age (years)   | 68.1 ± 7.9    | 69.0 ± 5.9    | 0.732   |
| Sex (M/F)     | 9/18          | 6/7           | 0.785   |
| Age at onset  | 60.0 ± 7.5    | 62.4 ± 8.1    | 0.371   |
| Disease duration (years) | 8.1 ± 2.7 | 7.3 ± 2.8 | 0.382 |
| Pyramidal score | 60.0 ± 7.5 | 41.9 ± 17.9 | 0.017 |

MSA-C, multiple system atrophy cerebellar type; MSA-P, multiple system atrophy parkinsonian type. p < 0.05 are in italics. ^1Independent two sample t-test. ^2Chi-squared test.
diagnosis of probable MSA and possible MSA during life (Table S3). We were able to study 38 cases1 AD type changes (Braak neurofibrillary tangle and CERAD staging) and Braak Lewy body staging. Our results showed that majority of cases examined did not have co-existent Alzheimer-type pathology (CERAD = 0 in 32 cases, A in three cases, B in two case, and C in one case; Braak neurofibrillary tangle staging = zero in six cases, 1 in 11 cases, II in 10 cases, III in five cases, IV in five cases, and V in one case; NIA-Reagan probability of AD: no evidence of AD for 32 cases, low evidence for three cases, intermediate evidence for two cases, and high evidence for one case) or Lewy body pathology (Braak Lewy body staging = 0 in 34 cases, 2 in two cases, 3 in one case, and 4 in one case).

We next stratified patients into those with high pyramidal scores (P_H score ≥ 50) or low pyramidal scores (P_L score < 50). We found that P_H and P_L cases were similar in age of death, gender, age of symptoms onset, or disease duration (Table 2).

**Clinical correlates with pyramidal scores**

We next examined whether the pyramidal scores are associated with features of MSA. We found that, when compared to P_L cases, P_H cases are more likely to have stridor (OR = 4.89, p = 0.022), but less likely to have orthostatic hypotension (OR = 0.11, p = 0.006) and erectile dysfunction (OR = 0.05, p = 0.018), both of which belong to the autonomic dysfunction (Table 3). P_H cases did not have increased odds of having bowel dysfunction (constipation or fecal incontinence), RBD, dry eyes/mouth, dysarthria, and dysphagia compared to P_L cases (all p > 0.05).

**Table 2.** Clinical features of multiple system atrophy cases, stratified by clinical pyramidal scores.

| Clinical pyramidal scores | P_H (n = 20) | P_L (n = 40) | p-value |
|---------------------------|-------------|-------------|---------|
| Age^2                     | 68.4 ± 5.5  | 68.45 ± 8.75| 0.983   |
| Sex (M/F)^1               | 14/6        | 11/9        | 0.327   |
| Age at onset^2            | 60.4 ± 5.2  | 61.3 ± 9.6  | 0.715   |
| Disease duration (years)^2| 7.9 ± 2.7   | 7.9 ± 2.9   | 0.978   |
| Pyramidal score^3         | 64.3 ± 9.3  | 37.3 ± 9.0  | <0.001* |

Abbreviations: F, female; GCI, glial cytoplasmic inclusion; GCI0, GCI deposition is none (GCI = 0) or scanty/rare (GCI = 1); GCI1 = GCI deposition is scattered/numerous (GCI = 2) or widespread/everywhere (GCI = 3); M, male; MSA, multiple system atrophy; P/C, parkinsonism type/cerebellar type; P_H, high pyramidal scores (≥50); P_L, low pyramidal score (<50).

^1p < 0.05.

^1Independent two sample t-test.

^2Chi-squared test.

**Table 3.** Logistic regression analyses investigating the association between the pyramidal score and the core features seen in multiple system atrophy.

| Features                    | Odds ratio | p-value |
|-----------------------------|------------|---------|
| Urinary incontinence        | 2.25       | 0.206   |
| Orthostatic hypotension     | 0.11       | 0.006   |
| Erectile dysfunction^1       | 0.05       | 0.018   |
| Bowel dysfunction^2          | 0.80       | 0.736   |
| RBD                         | 0.58       | 0.465   |
| Stridor                     | 4.89       | 0.022   |
| Dry eyes                    | 0.75       | 0.105   |

Odds ratio of cases with high versus low pyramidal scores are displayed. Dependent variable: pyramidal score < 50 = 0, pyramidal score ≥ 50 = 1. RBD, rapid eye movement behavioral disorders. p < 0.05 are in italics.

^1Females excluded.

^2Bowel dysfunction includes constipation and fecal incontinence.

Finally, we determined whether pyramidal signs are associated with survival: we found P_H and P_L cases are not different in survival (P_H vs. P_L = 7.9 ± 2.7 years vs. 7.9 ± 2.9 years, p = 0.978). The results did not change after we stratified the MSA cases into MSA-P (P_H vs. P_L = 7.8 ± 2.7 years [n = 16] vs. 8.6 ± 2.8 years [n = 11], p = 0.870; H = 1.08, p = 0.322) and MSA-C (P_H vs. P_L = 8.3 ± 3.1 years [n = 4] vs. 6.9 ± 2.8 years [n = 9], p = 0.703; H = 1.20, p = 0.574). In addition, using multivariable regression analysis, we also found no association between pyramidal scores and survival (H = 0.24, p = 0.797, Table 4).

**Neuropathological correlates with pyramidal scores**

We next studied clinicopathological correlates by investigating if GCI density in the motor cortex and the adjacent white matter is associated with pyramidal scores. We found indeed that GCI_H cases have higher pyramidal scores compared to GCI_L cases (54.0 ± 14.7 vs. 39.4 ± 18.6, p = 0.017). Consistently, GCI_H cases have a
Table 5. Neuropathological assessments of multiple system atrophy cases, stratified by glial cytoplasmic inclusion density.

|                      | GCI density | GCI density | p-value |
|----------------------|-------------|-------------|---------|
| Age at death¹        | 68.1 ± 7.3  | 69.4 ± 7.4  | 0.637   |
| Sex (M/F)²           | 11/20       | 4/5         | 0.625   |
| Age at onset¹        | 60.2 ± 8.0  | 62.9 ± 6.3  | 0.359   |
| Disease duration/survival (years)¹ | 8.3 ± 2.4 | 6.5 ± 3.4  | 0.091   |
| Pyramidal score¹     | 54.0 ± 14.7 | 39.4 ± 18.6 | 0.017   |
| MSA subtype (P/C)²   | 24/7        | 3/6         | 0.013   |
| GCI density – motor cortex¹ | 2.6 ± 0.5 | 1.0 ± 0.0  | <0.001  |
| GCI density – pontine base¹ | 2.7 ± 0.8 | 2.0 ± 0.7  | 0.095   |
| GCI density – ION¹    | 2.0 ± 0.8   | 1.4 ± 0.5   | 0.154   |
| GCI density – cerebellar dentate and its adjacent white matter¹ | 2.5 ± 0.9 | 2.3 ± 0.3  | 0.612   |
| Motor cortex neuronal loss level¹ | 1.3 ± 0.9 | 0.4 ± 0.9  | 0.084   |
| NCI density – ION¹    | 1.7 ± 0.8   | 1.3 ± 1.0   | 0.480   |

CERAD, The Consortium to Establish a Registry for Alzheimer’s disease; F, female; GCI, glial cytoplasmic inclusion; GCIH, cases with GCI deposition in the motor cortex and its adjacent white matter rated as none (GCI = 0) or scanty/rare (GCI = 1); GCIl, cases with GCI deposition in the motor cortex and its adjacent white matter rated as scattered/numerous (GCI = 2) or widespread/everwhere (GCI = 3); the same method was applied to quantify the GCI density in other brain regions listed in the table; ION, inferior olivary nucleus; M, male; MSA, multiple system atrophy; NCI, neuronal cytoplasmic inclusion; P/C, parkinsonism type/cerebellar type; Ri, high pyramidal scores (≥50); Pli, low pyramidal score (<50); p < 0.05 are in italics.

¹Independent two sample t-test.
²Chi-squared test.

The association between pyramidal signs and autonomic dysfunction in MSA is complex and requires future exploration. Specifically, we found that patients with high pyramidal scores are less likely to have orthostatic hypotension and erectile dysfunction. These observations may be partly explained by the fact that autonomic dysfunction in MSA can result from the pathological involvement of the preganglionic neurons of the central autonomic pathway at different levels, creating diverse autonomic symptoms. The finding of less erectile dysfunction may imply less parasympathetic involvement in MSA cases with higher pyramidal scores.

MSA pathology was hypothesized to have a prion-like spreading pattern. How do we factor our findings into the prion-like spreading of MSA pathology in the central nervous system? Since we have identified that MSA-P cases are more likely to have higher pyramidal scores, which correlate with the density of GCIls in the motor cortex, it is plausible that alpha-synuclein pathology in the nigrostriatal pathway is more likely to reach the motor cortex, possibly via retrograde connection, given the direct connection between the motor cortex and basal ganglia. On the other hand, alpha-synuclein deposits in the cerebellum may need to go through several relays of brain areas such as the thalamus to reach the motor cortex. The other possibility is that MSA-P and MSA-C may have different alpha-synuclein “strains,” which potentially have differential properties to spread to the motor cortex. Further examination in experimental models will yield additional insight and help us to understand the pathomechanism of MSA.

A strength of this study is that all MSA cases are pathologically confirmed. To our knowledge, this is the first study unveiling the association between pyramidal signs and other clinical features in MSA. This is also the first study demonstrating the correlations between the pathologic burdens of GCIls in the motor cortex with pyramidal signs in MSA. There are several limitations of the present study. First, we do not have neuropathologic examination in the spinal cord, which is not included in the standard neuropathologic assessments of multiple system atrophy cases, stratified by glial cytoplasmic inclusion density.
protocol in the New York Brain Brank for MSA cases. Therefore, we were not able to examine the sacral Onuf’s nucleus and intermediolateral column, both of which contain neurons for autonomic function. Along this line, we were not able to examine the lateral corticospinal tract, which would be an additional correlate of pyramidal signs. Our study did not detect a statistically significant correlation between neuronal loss in motor cortex and GCIH versus GCI density. However, despite an often-high density of GCIs in motor cortex and its adjacent white matter, other pathological changes in motor cortex may be relatively unnoticeable, including that only up to ~20% neuronal loss could be detected. In addition, neuronal loss could be a relatively late manifestation. Thus, pyramidal tract dysfunction in MSA might be largely explained by the location of GCIs in oligodendrocytes, affecting the integrity of myelin, and transduction of action potentials along axons even before neuronal cell body loss is appreciable. Second, we studied the clinical features based on a retrospective review, rather than prospective, standardized assessment. Nonetheless, all medical records in these MSA cases were documented comprehensively by movement disorders neurologists in a single center at Columbia University with sufficient clinical data for the presence or absence of the clinical variables stated in the methodology. Lastly, while we found higher pyramidal scores are related to less parasympathetic involvement in MSA, we should cautiously interpret this finding, which may also reflect the variability in reporting symptoms such as erectile dysfunction from patients. Future studies should focus on detailed clinical-radiological studies to examine the degenerative patterns and more comprehensive neuropathologic investigations, such as neurofilament immunohistochemistry, to examine extent of axonal degeneration in the pyramidal system to fully characterize this under-recognized clinical domain for MSA.

Conclusions

Our study suggests that MSA cases with prominent pyramidal signs could belong to a rather distinct type with different constellations of autonomic, parkinsonian, and cerebellar symptoms.

Conflict of Interest

Authors report nothing to disclose.

Author Contribution

Chi-Ying R. Lin: study concept, data acquisition and interpretation, manuscript draft and revision. Anishka Viswanathan: extensive chart review and literature search. Tiffany X. Chen: comprehensive statistical analysis and data interpretation. Hiroshi Mitsumoto: critical revision of the manuscript for important intellectual content. Jean P. Vonsattel: data acquisition and interpretation. Phyllis L. Faust: study supervision, critical revision of the manuscript for important intellectual content. Sheng-Han Kuo: study concept, data interpretation, critical revision of the manuscript for important intellectual content, and study supervision.

References

1. Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med. 2015;372:249-263. doi:10.1056/NEJMoa1501163
2. Krismer F, Wenning GK. Multiple system atrophy: insights into a rare and debilitating movement disorder. Nat Rev Neurol. 2017;13:232-243. doi:10.1038/nrneurol.2017.26 [Pub 2017 Mar 17]
3. Burn DJ, Jaros E. Multiple system atrophy: cellular and molecular pathology. Mol Pathol. 2001;54:419-426.
4. Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain. 2002;125:1070-1083. doi:10.1093/brain/awf117
5. Calandra-Buonaura G, Gueraldì P, Sambati L, et al. Multiple system atrophy with prolonged survival: is late onset of dysautonomia the clue? Neurol Sci. 2013;34:1875-1878. doi:10.1007/s10072-013-1470-1 [Pub 2013 Jun 1]
6. Giannini G, Calandra-Buonaura G, Mastrolilli F, et al. Early stridor onset and stridor treatment predict survival in 136 patients with MSA. Neurology. 2016;(87):1375-1383. doi:10.1212/WNL.0000000000003156 [Pub 2016 Aug 26]
7. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670-676. doi:10.1212/01.wnl.0000324625.00404.15
8. Wenning GK, Shlomo YB, Magalhaes M, et al. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain. 1994;117:835-845. doi:10.1093/brain/117.4.835
9. da Rocha AJ, Maia ACM Jr, da Silva CJ, et al. Pyramidal tract degeneration in multiple system atrophy: the relevance of magnetization transfer imaging. Mov Disord. 2007;22:238-244. doi:10.1002/mds.21229
10. Köllensperger M, Geser F, Ndayisaba J-P, et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord. 2010;25:2604-2612. doi:10.1002/mds.23192
11. Tsuchiya K, Ozawa E, Haga C, et al. Constant involvement of the Betz cells and pyramidal tract in
multiple system atrophy: a clinicopathological study of seven autopsy cases. Acta Neuropathol. 2000;99:628-636. doi:10.1007/s004010051173

12. Watanabe H, Riku Y, Hara K, et al. Clinical and imaging features of multiple system atrophy: challenges for an early and clinically definitive diagnosis. J Mov Disord. 2018;11:107-120. doi:10.14802/jmd.18020 [Epub 2018 Aug 9]

13. Ramirez EP, Vonsattel JP. Neuropathologic changes of multiple system atrophy and diffuse Lewy body disease. Semin Neurol. 2014;34:210-216. doi:10.1055/s-0034-1381732 [Epub 2014 Jun 25]

14. Cortelli P, Calandra-Buonaura G, Benarroch EE, et al. Stridor in multiple system atrophy: consensus statement on diagnosis, prognosis, and treatment. Neurology. 2019;93:630-639. doi:10.1212/WNL.0000000000008208

15. Conway KS, Camelo-Piragua S, Fisher-Hubbard A, Perry WR, Shakkottai VG, Venneti S. Multiple system atrophy pathology is associated with primary Sjögren’s syndrome. JCI Insight. 2020;5:e138619. doi:10.1172/jci.insight.138619

16. Mezzapesa DM, D’Errico E, Tortelli R, et al. Cortical thinning and clinical heterogeneity in amyotrophic lateral sclerosis. PLoS One. 2013;8:e80748. doi:10.1371/journal.pone.0080748 eCollection 2013.

17. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259. doi:10.1007/BF00308809

18. Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer’s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology. 1991;41(479):479-486.

19. Newell KL, Hyman BT, Growdon JH, Hedley-Whyte ET. Application of the National Institute on Aging (NIA)-Reagan institute criteria for the neuropathological diagnosis of Alzheimer disease. J Neuropathol Exp Neurol. 1999;58(11):1147-1155. doi:10.1097/00005072-199911000-00004

20. Braak H, Tredici KD, Réub U, de Vos RAJ, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197-211.

21. van der Graaff MM, Grolman W, Westermann EJ, et al. Vocal cord dysfunction in amyotrophic lateral sclerosis: four cases and a review of the literature. Arch Neurol. 2009;66:1329-1333. doi:10.1001/archneur.2009.250

22. Simonds AK. Progress in respiratory management of bulbar complications of motor neuron disease/amyotrophic lateral sclerosis? Thorax. 2017;72:199-201. doi:10.1136/thoraxjnl-2016-208919 [Epub 2016 Aug 12]

23. Cohen J, Low P, Fealey R, Sheps S, Jiang NS. Somatic and autonomic function in progressive autonomic failure and multiple system atrophy. Ann Neurol. 1987;22:692-699. doi:10.1002/ana.410220604

24. McLeod JG, Tuck RR. Disorders of the autonomic nervous system: part 1. Pathophysiol clin features. Ann Neurol. 1987;21:419-430. doi:10.1002/ana.410210502

25. Watts JC, Giles K, Oehler A, et al. Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci. 2013;110:19555-19560. doi:10.1073/pnas.1318268110

26. Foffani G, Obeso JA. A cortical pathogenic theory of Parkinson’s disease. Neuron. 2018;99:1116-1128. doi:10.1016/j.neuron.2018.07.028

27. Lau A, So RWL, Lau HHC, et al. a-Synuclein strains target distinct brain regions and cell types. Nat Neurosci. 2020;23(1):21-31. doi:10.1038/s41593-019-0541-x [Epub 2019 Dec 2]

28. Holec SAM, Woerman AL. Evidence of distinct a-synuclein strains underlying disease heterogeneity. Acta Neuropathol. 2021;142(1):73-86. doi:10.1007/s00401-020-02163-5 [Epub 2020 May 21]

29. Su M, Yoshida Y, Hirata Y, Watahiki Y, Nagata K. Primary involvement of the motor area in association with the nigrostriatal pathway in multiple system atrophy: neuropathological and morphometric evaluations. Acta Neuropathol. 2001;101(1):57-64. doi:10.1007/s004010000273

30. Jellinger KA. Neuropathology of multiple system atrophy: new thoughts about pathogenesis. Mov Disord. 2014;29(14):1720-1741. doi:10.1002/mds.26052 [Epub 2014 Oct 9]

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. Scale for clinical pyramidal burden applied in the present study.

Table S2. Prevalence of each clinical variables of interest.

Table S3. Severity of hyperreflexia and upper motor neuron signs between probable versus possible multiple system atrophy.